Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
CIPLA | SUN PHARMA | CIPLA/ SUN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 29.2 | 77.3 | 37.8% | View Chart |
P/BV | x | 4.1 | 3.3 | 125.1% | View Chart |
Dividend Yield | % | 0.5 | 0.6 | 76.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-20 |
SUN PHARMA Mar-20 |
CIPLA/ SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 586 | 484 | 120.9% | |
Low | Rs | 357 | 315 | 113.2% | |
Sales per share (Unadj.) | Rs | 207.0 | 136.9 | 151.3% | |
Earnings per share (Unadj.) | Rs | 18.6 | 17.5 | 106.6% | |
Cash flow per share (Unadj.) | Rs | 33.2 | 26.0 | 127.5% | |
Dividends per share (Unadj.) | Rs | 4.00 | 4.00 | 100.0% | |
Dividend yield (eoy) | % | 0.8 | 1.0 | 84.8% | |
Book value per share (Unadj.) | Rs | 195.5 | 188.7 | 103.6% | |
Shares outstanding (eoy) | m | 806.35 | 2,399.26 | 33.6% | |
Bonus/Rights/Conversions | ESOS | - | - | ||
Price / Sales ratio | x | 2.3 | 2.9 | 77.9% | |
Avg P/E ratio | x | 25.3 | 22.9 | 110.6% | |
P/CF ratio (eoy) | x | 14.2 | 15.4 | 92.4% | |
Price / Book Value ratio | x | 2.4 | 2.1 | 113.8% | |
Dividend payout | % | 21.5 | 22.9 | 93.8% | |
Avg Mkt Cap | Rs m | 379,912 | 958,864 | 39.6% | |
No. of employees | `000 | 25.8 | 17.8 | 145.5% | |
Total wages/salary | Rs m | 30,270 | 63,624 | 47.6% | |
Avg. sales/employee | Rs Th | 6,459.6 | 18,490.6 | 34.9% | |
Avg. wages/employee | Rs Th | 1,171.2 | 3,582.6 | 32.7% | |
Avg. net profit/employee | Rs Th | 580.2 | 2,357.6 | 24.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 166,949 | 328,375 | 50.8% | |
Other income | Rs m | 3,442 | 6,360 | 54.1% | |
Total revenues | Rs m | 170,391 | 334,735 | 50.9% | |
Gross profit | Rs m | 32,060 | 69,898 | 45.9% | |
Depreciation | Rs m | 11,747 | 20,528 | 57.2% | |
Interest | Rs m | 1,974 | 3,027 | 65.2% | |
Profit before tax | Rs m | 21,782 | 52,702 | 41.3% | |
Minority Interest | Rs m | -475 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -2,606 | 0.0% | |
Tax | Rs m | 6,312 | 8,228 | 76.7% | |
Profit after tax | Rs m | 14,995 | 41,868 | 35.8% | |
Gross profit margin | % | 19.2 | 21.3 | 90.2% | |
Effective tax rate | % | 29.0 | 15.6 | 185.6% | |
Net profit margin | % | 9.0 | 12.8 | 70.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 117,038 | 316,542 | 37.0% | |
Current liabilities | Rs m | 43,931 | 157,064 | 28.0% | |
Net working cap to sales | % | 43.8 | 48.6 | 90.2% | |
Current ratio | x | 2.7 | 2.0 | 132.2% | |
Inventory Days | Days | 96 | 88 | 109.3% | |
Debtors Days | Days | 85 | 105 | 81.2% | |
Net fixed assets | Rs m | 107,424 | 243,102 | 44.2% | |
Share capital | Rs m | 1,613 | 2,399 | 67.2% | |
"Free" reserves | Rs m | 156,018 | 450,245 | 34.7% | |
Net worth | Rs m | 157,630 | 452,645 | 34.8% | |
Long term debt | Rs m | 23,693 | 20,289 | 116.8% | |
Total assets | Rs m | 236,626 | 682,525 | 34.7% | |
Interest coverage | x | 12.0 | 18.4 | 65.4% | |
Debt to equity ratio | x | 0.2 | 0 | 335.3% | |
Sales to assets ratio | x | 0.7 | 0.5 | 146.6% | |
Return on assets | % | 7.2 | 6.6 | 109.0% | |
Return on equity | % | 9.5 | 9.2 | 102.8% | |
Return on capital | % | 12.8 | 11.2 | 114.3% | |
Exports to sales | % | 33.0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 55,175 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 56,036 | 74,219 | 75.5% | |
Fx outflow | Rs m | 6,764 | 27,964 | 24.2% | |
Net fx | Rs m | 49,272 | 46,255 | 106.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 30,685 | 65,548 | 46.8% | |
From Investments | Rs m | 1,040 | -25,888 | -4.0% | |
From Financial Activity | Rs m | -29,488 | -57,151 | 51.6% | |
Net Cashflow | Rs m | 2,340 | -13,857 | -16.9% |
Indian Promoters | % | 16.0 | 63.7 | 25.1% | |
Foreign collaborators | % | 20.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 12.2 | 5.1 | 237.8% | |
FIIs | % | 23.7 | 23.0 | 103.0% | |
ADR/GDR | % | 1.1 | 0.0 | - | |
Free float | % | 26.2 | 8.3 | 315.7% | |
Shareholders | 161,166 | 133,026 | 121.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.5 | - |
Compare CIPLA With: BIOCON CADILA HEALTHCARE VENUS REMEDIES PANACEA BIOTECH GLENMARK PHARMA
Compare CIPLA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 385 points, down 0.8% at 51,059 levels.
For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
An Indian company founded three decades ago in a garage caught my attention...
More